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Circulating Tyrosinase and MART-1 mRNA does not
Independently Predict Relapse or Survival in Patients
with AJCC Stage I–II Melanoma
Henrik Schmidt1, Boe S. Sorensen2, Pia Sjoegren3, Ib Jarle Christensen4, Kirsten Fode1, Jorn Larsen3,
Ebba Nexo2 and Hans von der Maase1
The detection of melanoma cells in peripheral blood has been proposed to select patients with a high risk of
relapse. In this study, tyrosinase and melanoma antigen recognized by T cells 1 (MART-1) mRNA expression was
evaluated in serial samples obtained before definitive surgery and during follow-up in patients with American
Joint Committee on Cancer stage I–II melanoma. Serial samples (n¼ 2,262) were collected from 236 patients
from 1997 to 2002. Analyses of the RNA samples were performed with a calibrated reverse transcriptase-PCR
assay. Gender, age, primary tumor site, ulceration, thickness, Clark level, and histological subtype were analyzed
together with tyrosinase and MART-1 mRNA treated as updated covariates in a Cox proportional-hazard model.
After a median follow-up time of 66 months, 42 out of 236 patients (18%) had relapsed. The following variables
were significantly associated with relapse-free survival in the univariate analyses: tyrosinase, MART-1, gender,
ulceration, thickness, Clark level, and histological subtype. Entering these covariates into a multivariate Cox
analysis resulted in thickness as the single independent prognostic factor (Po0.0001), whereas MART-1 (P¼ 0.07)
approached significance at the 5% significance level. The serial measurements of tyrosinase and MART-1 mRNA
in peripheral blood of stage I–II melanoma patients cannot be demonstrated to have independent prognostic
impact on relapse-free survival.
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INTRODUCTION
The detection of circulating melanoma cells with reverse
transcriptase (RT)-PCR has been proposed as an effective tool
in selecting patients with a high risk of relapse before
enrolment in adjuvant treatment studies (Curry et al., 1998;
Ghossein et al., 1998).
Tyrosinase and and melanoma antigen recognized by
T cells 1 (MART-1) are two of the most specific proteins
involved in melanocytic differentiation (Battyani et al., 1993;
Kawakami et al., 1994) and the detection of tyrosinase and
MART-1 mRNA in peripheral blood have been evaluated in a
number of studies (Hoon et al., 1995; Palmieri et al., 1999;
Keilholz et al., 2004; Schmidt et al., 2005). The majority of
these studies have investigated American Joint Committee on
Cancer (AJCC) stage III–IV patients and only few patients with
stage I–II melanoma have been followed with serial blood
samples for a sufficient follow-up time. Thus, we know little
about the prognostic impact of tyrosinase and MART-1 mRNA
in peripheral blood of stage II patients and even less in stage I
patients. The meta-analysis by Tsao et al. (2001) suggested that
tyrosinase mRNA was of limited value given the unreliability of
the procedure and the lack of sufficient follow-up in studies
with stage I–III patients. In a recent meta-analysis, specifically
addressing the relationship between serial blood samples
during follow-up in relation to relapse, it was concluded that
tyrosinase mRNA was a potentially useful marker, at least in the
follow-up of stage III patients (Quaglino et al., 2004).
In the current study, we examined serial blood samples for
circulating melanoma cells, based on tyrosinase and MART-1
mRNA expression, from the time of definitive surgery of the
primary lesion and during follow-up in 236 consecutive stage
I–II melanoma patients.
RESULTS
This study was conducted on serial blood samples from 236
stage I–II melanoma patients. A total of 2,262 serum samples
were collected before definitive surgery and during the
follow-up period. The median number of samples collected
from each patient was 10, with a range from 1 to 15 samples
(one sample, 4%; two to seven samples, 14%; eight to ten
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samples, 38%; 11 to 15 samples, 44%). The median follow-
up interval between the first sample and the last follow-up or
death was 66 months (range 1–97 months). The median
follow-up interval from the first to the last blood sample was
36 months (range 1–66 months). The patients’ characteristics
are summarized in Table 1.
Tyrosinase and MART-1
Tyrosinase and MART-1 was observed in 111 (5%) and 172
samples (7%), respectively. Twenty-nine patients (12%) had a
positive determination of tyrosinase or MART-1 before
definitive surgery. Of these, 20 patients were stage I and
nine patients stage II. During the follow-up time, 142 patients
(60%) had at least one positive determination of tyrosinase or
MART-1. In Figure 1 the percentage of positive tyrosinase and
MART-1 samples are shown as a function of time. The
proportion of patients with a positive sample during the
follow-up period was similar between stages IA and IIB
(Table 2). No significant associations or correlations were
observed between a positive baseline sample and gender,
age, ulceration, primary tumor site, thickness, Clark level,
and histological subtype. No correlations were observed for
patients with a positive follow-up sample and the above-
mentioned baseline risk factors. Control samples were
obtained from 89 individuals with nevi and non-melanoma
cancers. None of these samples were positive for tyrosinase.
However, two patients with nevi had a positive MART-1
analysis.
Association of serial tyrosinase and MART-1 and relapse-free
survival
Relapses during the follow-up time were observed in 42 out
of 236 patients (18%). One-half of the patients developed
distant metastases as their first relapse and the other half loco-
regional relapse. Of the 42 relapsing patients, no samples
were positive in 25 patients (60%), in 12 patients (29%) at
least one sample was positive more than 6 months before
relapse, and finally in five patients (11%) at least one sample
was positive within 6 months before relapse. Follow-up
samples were obtained after surgical excision of a local
relapse in seven patients. In three of these patients, positive
samples were also seen after surgery.
In the univariate analyses, the following variables were
significantly (Po0.10) associated with relapse-free survival:
tyrosinase mRNA, MART-1 mRNA, gender, ulceration,
thickness, Clark level, and histological subtype (Table 3).
Tyrosinase and MART-1 (negative versus positive) were both
considered as updated covariates owing to the serial
measurements. Entering these covariates into a multivariate
Cox analysis with backward selection resulted in thickness
as an independent prognostic factor (hazard ratio (HR) 4.1,
95% confidence interval (CI), 2.7–6.2; Po0.0001). MART-1
(HR 3.1, 95% CI, 0.9–10.2; P¼ 0.07) was close to achieving
significance at the 5% significance level, whereas
tyrosinase (HR 2.7, 95% CI, 0.4–16.7; P¼ 0.36) was not
significant. Tyrosinase and MART-1 were also substituted
with the combination of tyrosinase and MART-1 treated
as one covariate (negative versus at least one positive). In the
univariate analysis, a significant correlation was observed
between a positive tyrosinase and MART-1 and a short
relapse-free survival (HR 3.7, 95% CI, 1.5–9.1; P¼0.005).
Entering this covariate into the multivariate analysis
together with gender, ulceration, thickness, Clark level,
and histological subtype resulted again in thickness as the
single independent prognostic factor, whereas the combina-
tion of tyrosinase and MART-1 was not significant (HR 1.5,
95% CI, 0.5–4.8; P¼0.11). When analyzing tyrosinase
and MART-1 results in only the baseline samples, no
Table 1. Demographic and pathologic data for 236
patients with AJCC stage I–II melanoma
AJCC stage
I (n=164) II (n=72) Total (n=236)
No. % No. % No. %
Gender
Female 93 57 50 69 115 49
Male 71 43 22 31 121 51
Age (years)
Median 52 60 56
Range 25–81 25–86 25–86
Ulceration
None 160 98 35 49 195 83
Present 4 2 37 51 41 17
Histological subtype
SSM 150 91 26 36 176 75
Others 14 9 45 63 59 25
Missing1 0 0 1 0.4 1 0.4
Thickness (mm)
Median 0.8 2.8 1.1
Range 0.2–2.0 1.1–21.0 0.2–21.0
Missing1 0 0 12 17 12 5
Clark level
Level I–III 144 88 21 29 165 70
Level IV–V 20 12 41 57 61 26
Missing1 0 0 10 14 10 4
Primary tumour site
Head and trunk 95 58 44 61 139 59
Limbs 69 42 28 39 97 41
AJCC, American Joint Committee on Cancer version 2001; SSM, super-
ficial spreading melanoma.
1Missing, tumours with an incomplete histopathological report.
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significant correlation to relapse-free survival was observed
(data not shown).
DISCUSSION
Studies in which circulating tumor cells are detected with
RT-PCR technology in serial blood samples are rare as
demonstrated in a recent meta-analysis (Quaglino et al.,
2004). We identified five studies comparable to our own as
shown in Table 4. Only patients with stage I–II melanomas
were included in this table, but the total number of patients in
these studies is noted. Disease stage in these studies was
reported according to the AJCC version 1994, and our data
were adjusted accordingly. Two studies included patients
with stage II–III disease (Garbe et al., 2003; Voit et al., 2005),
whereas the other studies included patients with stage
I–IV disease (Curry et al., 1999; Hanekom et al., 1999;
Brownbridge et al., 2001). Curry et al. (1999) showed
tyrosinase to be an independent prognostic factor for
disease-free survival in the subgroup of patients with
disseminated relapse, whereas MART-1 was an independent
prognostic factor for disease-free survival in the subgroup of
patients with loco-regional relapse. However, the analyses
were performed in subgroups and not in the total patient
cohort. The recent study by Voit et al. (2005) indicated a
strong association between tyrosinase and a reduced disease-
specific survival. The conclusion in these two studies was
primarily based on patients with stage II–III disease. The three
other studies did not report a prognostic impact of tyrosinase
and/or MART-1, although the follow-up time in the study by
Garbe et al. is too short for any valid conclusion.
There are a number of differences between our study and
the above referenced. Only the study by Hanekom et al.
Table 2. Frequency of patients with tyrosinase or MART-1 mRNA during follow-up after definitive surgery
according to stage, relapse rate, and 5-year survival rate
AJCC
stage
Number of
patients (%)
Number of patients
with tyrosinase or
MART-1 mRNA (%) Relapse rate n (%)
5-year overall
survival (%)
Expected 5-year
survival1 (%)
IA 104 (44) 66 (63) 6 (6) 98 95
IB 59 (25) 31 (52) 6 (10) 90 90
IIA 32 (14) 23 (72) 8 (25) 66 78
IIB 28 (12) 18 (64) 13 (46) 64 65
IIC 13 (5) 4 (31) 9 (69) 54 45
Total 236 (100) 142 (60) 42 (18) 85
AJCC, American Joint Committee on Cancer version 2001; MART-1, melanoma antigen recognized by T cells.
1Expected 5-year survival rate according to Balch et al. (2001).
Table 3. Univariate and multivariate Cox analyses of potential parameters of relapse-free survival in patients with
AJCC stage I–II melanoma
Univariate analyses Multivariate analysis
1
Covariates Categories compared P-value Hazard ratio 95% CI P-value
Updated covariates
Tyrosinase mRNA Negative versus positive 0.03 2.7 0.4–16.7 0.36
MART-1 mRNA Negative versus positive 0.06 3.1 0.9–10.2 0.07
Fixed covariates
Gender Female versus male 0.001 0.19
Age o median versus Xmedian 0.13
Ulceration None versus ulceration o0.0001 0.14
Primary tumor site Limbs versus others 0.15
Thickness (log transformed) Continuous covariate o0.0001 4.1 2.7–6.2 o0.0001
Clark level I–III versus IV–V o0.0001 0.22
Histological subtype SSM versus others o0.0001 0.75
AJCC, American Joint Committee on Cancer version 2001; MART-1, melanoma antigen recognized by T cells.
1All other significant covariates from the univariate analyses were not significant and therefore excluded from the model. N=224 patients, 38 relapses.
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collected blood samples from the time of diagnosis as we did.
Apart from our own study, only Voit et al. analyzed tyrosinase
as an updated covariate in a Cox regression analysis. This
method can evaluate serial measurements in the context of
time and should be considered in studies analyzing serial
measurements. In our study, the presence of tyrosinase and
MART-1 mRNA in serial blood samples from the time of
diagnosis and during the follow-up time was not independent
prognostic factors for relapse-free survival, but MART-1
(P¼0.07) approached the 5% significance level. In a recent
meta-analysis specifically addressing the relationship be-
tween serial blood samples during follow-up in relation to
relapse, it was concluded that tyrosinase mRNA was a
potentially useful marker, at least in the follow-up of stage III
patients (Curry et al., 1999; Osella-Abate et al., 2003;
Quaglino et al., 2004). In our study, 12% of stage I patients
were positive for tyrosinase or MART-1 in the baseline
sample compared to 13% of patients with stage II.
Additionally, no difference in the frequency of positive
samples was seen between stages I and II during the follow-
up period (Table 2). This is in contrast to a number of studies
in which the frequency of a positive sample increases
significantly with stage (Mellado et al., 1996; Palmieri
et al., 1999; Proebstle et al., 2000).
None of the 89 control individuals in our study were
positive for tyrosinase, but two individuals (2%) with benign
nevi had one sample positive for MART-1. In the literature,
Keilholz et al. (2004) has previously reported false-positive
MART-1 analyses in three of 21 healthy volunteers. None of
the two positive controls in our study were later diagnosed
with a relapse or a new melanoma during the follow-up
periods of 4.5 and 8 years, respectively. It remains an
academic discussion whether these two samples were false
positive or that these patients had a non-diagnosed mela-
noma. The latter option cannot be ruled out because all
control patients with nevi were included in the study with the
clinical suspicion of a melanoma. Reports of positive
tyrosinase determinations in control subjects are rare. The
meta-analysis by Tsao et al. (2001) suggested that the false-
positive rate is about 0.37%. However, the false-positive rate
is probably underestimated, as none of the studies, including
our own one, examined serial control samples. Thus, the
percentage of positive findings in our controls may have been
higher, if several samples would have been taken. One
explanation of false-positive samples could be contamination
during the RNA extraction and RT-PCR analysis. However,
RNA extraction, PCR reagent setup, and handling of PCR
products were performed in separate rooms to avoid potential
cross-contamination and negative and positive controls were
used with each and every RT-PCR analysis.
We compared the 5-year survival rates in our patients with
the material published by Balch et al. (2001). There was a
good correlation stage by stage, especially in stage I patients,
indicating that the patients in our material acted as expected.
Table 4. Studies on consecutive RT-PCR detection of tyrosinase and MART-1 mRNA in AJCC stage I–II melanoma
AJCC stage
Study (year) Marker(s)
Total
number I II Samples collected from
Median
number
of assays
per patient
Median
follow-up
(months)
Multivariate
analysis Interpretation
Curry et al. (1999) Tyrosinase, MART-1 186 13 76 Definitive surgery+
follow-up
NR 35 Yes Positive1
Hanekom et al. (1999) Tyrosinase 143 76 67 Definitive surgery NR 48 NR Negative2
Brownbridge et al. (2001) Tyrosinase, MART-1 299 28 41 Definitive surgery+
follow-up
3 NR NR Negative2
Garbe et al. (2003) Tyrosinase, MART-1 296 0 167 Follow-up NR 19 NR Negative3
Voit et al. (2005) Tyrosinase 111 0 78 Follow-up NR 75 Yes Positive3
This study (2006) Tyrosinase, MART-1 236 157 79 Definitive surgery 10 66 Yes Negative
AJCC stage, American Joint Committee on Cancer stage version 1994; MART-1, melanoma antigen recognized by T cells; NR, not reported; n, total number
of patients with stage I and II disease.
1Conclusion was based on data from stage I–III disease.
2Conclusion was based on data from stage I–IV disease.
3Conclusion was based on data from stage II–III disease.
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Figure 1. The percentage of tyrosinase and MART-1 mRNA-positive blood
samples from 236 patients with AJCC stage I–II melanoma at the time of
diagnosis (month 0) and during follow-up.
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Patients with stage IIc had a better 5-year survival than
expected and patients with stage IIa had a worse survival.
This was probably owing to the low number of patients in
each of stages IIa–c and the fact that 12 patients with missing
tumor thickness were assigned to stages IIb and c.
Our data showed that tyrosinase and MART-1 was
infrequently detected (5–7% of the total samples). However,
based on the high number of serial samples, we observed a
high frequency of patients with at least one positive sample as
seen in Table 2. In fact, tyrosinase or MART-1 was detected
during follow-up in 60 and 62% of patients with stage I–II
disease, respectively. Our data raises the question whether
tyrosinase and/or MART-1 mRNA in peripheral blood as an
indicator of circulating melanoma cells have any clinical
implications for the patient. A recent study in breast cancer
patients detected circulating tumor cells in 13 of 36 patients
between 7 and 22 years after mastectomy in patients without
the evidence of malignant disease (Meng et al., 2004). The
half-life of circulating tumor cells in breast cancer was
reported between 1 and 2.4 hours! The authors concluded
that these patients must have had tumor cells somewhere in
the tissues, that replenished the dying cells in the blood, and
that this could represent one of the mechanisms underlying
tumor dormancy. Dormancy and long-term relapses are also
well known in melanoma (Shaw et al., 1985; Tsao et al.,
1997), but the reported frequency of long-term relapses is
reported as low as 0.7% (Tsao et al., 1997). The low ‘‘false-
positive’’ rate in controls in our study suggests that stage I–II
melanoma patients with a positive RT-PCR result may have
dormant tumor cell deposits. Thus, in order to examine
whether melanoma patients continue to have intermittent
positive samples without relapsing, a re-analysis after 10–15
years is warranted. However, the frequency of patients being
at least once positive was much greater than the expected
relapse rate and deaths in stage I–II melanoma (Table 2). It is
not realistic, given the length of our follow-up that many
more patients will relapse.
In conclusion, our study cannot demonstrate that tyrosi-
nase and MART-1 mRNA has independent prognostic impact
on relapse-free survival in stage I–II melanoma patients.
MATERIALS AND METHODS
Patients
The study was conducted as a prospective collection of blood
samples in 236 consecutive patients with AJCC stage I–II melanoma
from February 1997 to December 2002. The local ethics committee
of Aarhus County accepted the present project, and a written
informed consent was obtained from each patient. The study was
conducted according to the Declaration of Helsinki Principles.
Blood samples were collected before definitive primary surgery and
during follow-up until 2 years after inclusion of the last patient.
Baseline staging procedures for all patients included a chest X-ray
together with a full blood count including liver enzymes. Sentinel
node procedures were not performed routinely during this study.
Disease status was coded according to the AJCC guidelines version
2001 (Balch et al., 2001). Tumor thickness could not be measured in
12 patients (5%) owing to incomplete resection (eight patients),
regression (one patient), and technical problems (three patients),
respectively. These patients were coded as thick melanomas (stage
IIB), except for lesions with ulceration, which were coded as IIC.
Follow-up was performed every 3 months for the first 2 years and
then every 6 months up to 5 years. At each visit, a clinical history,
physical examination, and blood samples for RT-PCR analyses were
obtained. Diagnostic imaging, that is, X-ray, ultrasonography, or
computed tomography were performed if clinically indicated. In the
event of regional or distant relapse, patients were excluded from this
study; only patients with a local relapse were followed after surgical
excision.
Control samples were obtained from 89 individuals, 35 had
benign nevi and 55 had a cancer other than melanoma. The latter
group consisted of a variety of cancers, such as gynecological
(n¼ 11), breast (n¼ 10), urogenital (n¼ 7), head and neck (n¼ 7),
skin (n¼ 6), sarcoma (n¼ 5), lung (n¼ 4), and others (n¼ 6).
Reverse transcriptase-PCR
To avoid contamination by normal skin melanocytes during blood
sampling, the blood for RNA extraction were collected after serum
samples (Hanekom et al., 1997). The RNA extraction, PCR reagent
setup, and handling of PCR products were performed in separate
rooms to avoid potential cross-contamination in PCR. Total cellular
RNA was extracted using the RNeasy blood mini kit (Qiagen,
Chatsworth, CA) as outlined by the manufacturer. All samples were
processed within 4 hours on the day of collection. Samples were
stored at 801C until analyzed in a blinded manner. Primer
sequences and RT-PCR conditions have been described previously
(Schmidt et al., 2002). Quantification of the patient RNA samples
was performed with a calibrated RT-PCR design as described
previously (Sorensen et al., 2000). Integrity of RNA was determined
by performing parallel RT-PCR assays using primers specific for the
housekeeping gene b-actin. Blood samples that failed to amplify
products for b-actin RNA were considered non-informative and
discarded.
Statistics
The Wilcoxon rank-sum test and Spearman correlation were used to
test for associations and correlations between baseline tyrosinase
and MART-1 mRNA on one hand and clinical and pathological
characteristics on the other hand. Relapse-free survival was
calculated as the time from definitive surgery to the date of
progression or last follow-up. For relapse-free survival, patients
without an updated measurement (approximately 6 months) after the
latest update were removed from the risk set and only re-entered if a
measurement subsequently was available. All data on duration of
disease-free survival were updated on 1 May 2005 and calculations
were carried out using SAS software (SAS Institute, Cary, NC; version
9.1). All P-values are two-sided and values less than 5% are
considered significant.
The simultaneous relationship of multiple prognostic factors
for survival was assessed using Cox’s proportional-hazards model
with backward reduction. Factors with a P-value less than 0.10 in
the univariate analyses were included in the multivariate analysis
to identify factors of independent significance. The assumption
of proportional hazards was verified graphically with log (log (S))
versus time plots. The prognostic factors used for covariate
selection were the following: gender (female versus male), age
(omedian age versus Xmedian age), primary tumor site (limbs
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versus other sites), ulceration (none versus ulceration), Clark level
(level I–III versus IV–V), tumor thickness (logarithmically transformed
values), and histological subtype (superficial spreading melanoma
versus others). Tyrosinase/MART-1 mRNA (negative versus positive)
was considered as updated (time-dependent) covariates because
results changed over time, and several samples were available from
each patient.
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